Ponatinib

Summary

Ponatinib (CHEMBL1171837) is an approved small-molecule antineoplastic agent (ATC L01EA05) targeting ABL1, CDK19, and CDK8; indicated across 14 conditions including neoplasm and acute lymphoblastic leukemia.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: L01EA05
• Targets: 7 (ABL1, CDK19, CDK8…)
• Indications: 14 conditions
• Clinical trials: 58
• Chemistry: 532.6 Da · C29H27F3N6O

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1171837
Name	Ponatinib
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	24826799
ChEBI	CHEBI:78543
ATC	L01EA05
Molecular formula	C29H27F3N6O
Molecular weight	532.6
InChIKey	PHXJVRSECIGDHY-UHFFFAOYSA-N

SMILES: CC1=C(C=C(C=C1)C(=O)NC2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)C#CC4=CN=C5N4N=CC=C5

IUPAC name: 3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]benzamide

ChEBI definition: A benzamide obtained by the formal condensation of the carboxy group of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methylbenzoic acid with the anilino group of 4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)aniline. It is a multi-target tyrosine kinase inhibitor that targets ABL, SRC, FGFR, and others and was designed to overcome the resistance of BCR-ABL mutation to imatinib, in particular the gatekeeper mutation ABLT315I.

Pharmacological roles (ChEBI): antineoplastic agent, tyrosine kinase inhibitor.

Also known as: AP-24534, AP24534, Iclusig, Ponatinib, PONATINIB, SID137275996, ponotinib, ponatinib, ponaitinib, PONATINIB (AP24534), Ponatinib (AP24534), PONATINIB_ICLUSIG

Parent form; salt/anhydrous children: CHEMBL2105708

Patent coverage: 3,766 distinct patent families (8,955 SureChEMBL compound mentions), from 4 matched compound structure(s). One matched structure accounts for 8,382 (94%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
ABL1	ABL proto-oncogene 1, non-receptor tyrosine kinase	Inhibition	8.1	1.2%	P00519
CDK19	cyclin dependent kinase 19	Inhibition	7.92	0.1%	Q9BWU1
CDK8	cyclin dependent kinase 8	Inhibition	8.17	6.5%	P49336
RET	ret proto-oncogene	Inhibition	8.2	0.4%	P07949
RIPK1	receptor interacting serine/threonine kinase 1	Inhibition	7.92	0.3%	Q13546
RIPK2	receptor interacting serine/threonine kinase 2	Inhibition	7.85	0.2%	O43353
RIPK3	receptor interacting serine/threonine kinase 3	Inhibition	8.8	4.1%	Q9Y572

Broader ChEMBL bioactivity targets: 112 (assay-derived). Sample: Leucine-rich repeat serine/threonine-protein kinase 2, Receptor-interacting serine/threonine-protein kinase 3, Receptor tyrosine-protein kinase erbB-2, 5-hydroxytryptamine receptor 2B, Tyrosine-protein kinase Fyn, Macrophage colony-stimulating factor 1 receptor, Tyrosine-protein kinase ABL1, Vascular endothelial growth factor receptor 1, Neuronal acetylcholine receptor subunit alpha-4, Vasopressin V1a receptor.

Bioactivity

ChEMBL activities: 225 potent at pChembl ≥ 5 of 247 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
ABL1	10.3	EC50	0.05	nM	CHEMBL_ACT_16593631
HCK	9.96	IC50	0.11	nM	CHEMBL_ACT_22845497
LYN	9.8	IC50	0.16	nM	CHEMBL_ACT_22845499
LYN	9.62	IC50	0.24	nM	CHEMBL_ACT_17979955
LCK	9.55	IC50	0.28	nM	CHEMBL_ACT_22845495
FLT3	9.52	IC50	0.3	nM	CHEMBL_ACT_14545511
ABL1	9.52	EC50	0.3	nM	CHEMBL_ACT_16593639
RET	9.52	IC50	0.3	nM	CHEMBL_ACT_18002375
ABL1	9.52	IC50	0.3	nM	CHEMBL_ACT_22395843
ABL1	9.52	IC50	0.3	nM	CHEMBL_ACT_22395844
ABL1	9.52	IC50	0.3	nM	CHEMBL_ACT_22395845
ABL1	9.52	IC50	0.3	nM	CHEMBL_ACT_22395846
FLT3	9.52	IC50	0.3	nM	CHEMBL_ACT_24867168
ABL1	9.51	IC50	0.31	nM	CHEMBL_ACT_20609041
ABL1	9.49	IC50	0.32	nM	CHEMBL_ACT_12623367
ABL1	9.48	IC50	0.33	nM	CHEMBL_ACT_12623431
FYN	9.44	IC50	0.36	nM	CHEMBL_ACT_22845502
ABL1	9.43	IC50	0.37	nM	CHEMBL_ACT_17979954
ABL1	9.43	IC50	0.37	nM	CHEMBL_ACT_22395848
ABL1	9.43	IC50	0.37	nM	CHEMBL_ACT_22845504
ABL1	9.43	IC50	0.37	nM	CHEMBL_ACT_24707076
ABL1	9.43	IC50	0.37	nM	CHEMBL_ACT_24797177
ABL1	9.43	IC50	0.37	nM	CHEMBL_ACT_25663320
ABL1	9.43	IC50	0.37	nM	CHEMBL_ACT_3360733
ABL1	9.39	IC50	0.41	nM	CHEMBL_ACT_12623335
ABL1	9.37	IC50	0.43	nM	CHEMBL_ACT_12623351
ABL1	9.3	IC50	0.5	nM	CHEMBL_ACT_12623319
ABL1	9.3	IC50	0.5	nM	CHEMBL_ACT_14545510
ABL1	9.3	IC50	0.5	nM	CHEMBL_ACT_24867166
ABL1	9.24	IC50	0.58	nM	CHEMBL_ACT_12721731

Target pathways

Aggregated over 7 target gene(s): ABL1, CDK19, CDK8, RET, RIPK1, RIPK2, RIPK3.

Top Reactome pathways

113 total, by targets touching each:

Pathway	Targets	Genes
Developmental Biology	3	ABL1, CDK19, CDK8
Disease	3	ABL1, CDK19, CDK8
Infectious disease	3	ABL1, CDK19, CDK8
Metabolism	2	CDK19, CDK8
Signal Transduction	2	ABL1, CDK8
TICAM1, RIP1-mediated IKK complex recruitment	2	RIPK1, RIPK3
RIP-mediated NFkB activation via ZBP1	2	RIPK1, RIPK3
PPARA activates gene expression	2	CDK19, CDK8
Epigenetic regulation of gene expression	2	ABL1, CDK8
Generic Transcription Pathway	2	ABL1, CDK8
TRIF-mediated programmed cell death	2	RIPK1, RIPK3
TRP channels	2	RIPK1, RIPK3
Transcriptional regulation of white adipocyte differentiation	2	CDK19, CDK8
Regulation of lipid metabolism by PPARalpha	2	CDK19, CDK8
RIPK1-mediated regulated necrosis	2	RIPK1, RIPK3
Metabolism of lipids	2	CDK19, CDK8
Regulation of necroptotic cell death	2	RIPK1, RIPK3
Ovarian tumor domain proteases	2	RIPK1, RIPK2
RNA Polymerase II Transcription	2	ABL1, CDK8
Gene expression (Transcription)	2	ABL1, CDK8
TLR3-mediated TICAM1-dependent programmed cell death	2	RIPK1, RIPK3
IKK complex recruitment mediated by RIP1	2	RIPK1, RIPK3
Microbial modulation of RIPK1-mediated regulated necrosis	2	RIPK1, RIPK3
SARS-CoV-1-mediated effects on programmed cell death	2	RIPK1, RIPK3
Epigenetic regulation of gene expression by MLL3 and MLL4 complexes	2	ABL1, CDK8
Respiratory Syncytial Virus Infection Pathway	2	CDK19, CDK8
Viral Infection Pathways	2	CDK19, CDK8
RSV-host interactions	2	CDK19, CDK8
MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis	2	ABL1, CDK8
Adipogenesis	2	CDK19, CDK8

Dominant GO biological processes

GO term	Targets
protein phosphorylation	7
positive regulation of apoptotic process	4
positive regulation of transcription by RNA polymerase II	4
apoptotic process	4
signal transduction	4
canonical NF-kappaB signal transduction	3
positive regulation of canonical NF-kappaB signal transduction	3
regulation of cell cycle	3
cellular response to hydrogen peroxide	3
cellular response to lipopolysaccharide	3
response to oxidative stress	2
regulation of cell adhesion	2
neuron differentiation	2
positive regulation of type II interferon production	2
positive regulation of interleukin-2 production	2

Indications & clinical

Indications

14 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
neoplasm	3	MONDO:0005070	EFO:0000616
acute lymphoblastic leukemia	3	MONDO:0004967	EFO:0000220
chronic myeloid leukemia	3	MONDO:0011996	EFO:0000339
leukemia	2	MONDO:0005059	EFO:0000565
non-small cell lung carcinoma	2	MONDO:0005233	EFO:0003060
glioblastoma	2	MONDO:0018177	EFO:0000519
thyroid tumor	2	MONDO:0015074	EFO:0003841
acute myeloid leukemia	2	MONDO:0018874	EFO:0000222
small cell lung carcinoma	2	MONDO:0008433	EFO:0000702
lung adenocarcinoma	2	MONDO:0005061	EFO:0000571
blast phase chronic myelogenous leukemia, BCR-ABL1 positive	2	MONDO:0006115	EFO:1000131
gastrointestinal stromal tumor	2	MONDO:0011719	MONDO:0011719
myelodysplastic syndrome	1	MONDO:0018881	EFO:0000198

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 58.

Phase distribution

Phase	Trials
PHASE2	35
Not specified	10
PHASE1/PHASE2	6
PHASE3	3
PHASE2/PHASE3	2
PHASE1	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03589326	PHASE3	ACTIVE_NOT_RECRUITING	A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia
NCT04722848	PHASE3	ACTIVE_NOT_RECRUITING	Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL
NCT06860269	PHASE2/PHASE3	RECRUITING	A 3-cohort Randomized Study Evaluating the Role of New Immunotherapeutic Agents and of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Frontline Therapy of Adults With Acute Lymphoblastic Leukemia
NCT01650805	PHASE3	TERMINATED	Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
NCT01761747	PHASE2/PHASE3	TERMINATED	Ponatinib for Squamous Cell Lung and Head and Neck Cancers
NCT01424982	PHASE2	ACTIVE_NOT_RECRUITING	Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia
NCT03147612	PHASE2	ACTIVE_NOT_RECRUITING	Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia
NCT03263572	PHASE2	RECRUITING	Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia
NCT03739814	PHASE2	RECRUITING	Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
NCT03934372	PHASE1/PHASE2	RECRUITING	Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
NCT04070443	PHASE2	ACTIVE_NOT_RECRUITING	Safety and Efficacy of Ponatinib Followed by Imatinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase
NCT04160546	PHASE2	ACTIVE_NOT_RECRUITING	Study to Evaluate the Reinduction and Second Stop of TKI with Ponatinib in CML in Molecular Response (ResToP)
NCT04188405	PHASE2	ACTIVE_NOT_RECRUITING	Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia
NCT04475731	PHASE2	ACTIVE_NOT_RECRUITING	Ponatinib in Adult Ph+ ALL Patients With MRD Positivity or Hematological Relapse
NCT05306301	PHASE2	ACTIVE_NOT_RECRUITING	Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients
NCT06061094	PHASE2	RECRUITING	Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blinatumomab and SCT
NCT06207123	PHASE1/PHASE2	RECRUITING	A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)
NCT06813079	PHASE2	NOT_YET_RECRUITING	Using Tumor Models to Determine Treatments
NCT07224100	PHASE2	RECRUITING	Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma
NCT01207440	PHASE2	COMPLETED	Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL)
NCT01570868	PHASE2	TERMINATED	Ponatinib - Frontline for Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP)
NCT01620216	PHASE2	TERMINATED	Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
NCT01641107	PHASE2	COMPLETED	Phase II Front-line Ponatinib in Adult Philadelphia+/BCR-ABL+ Acute Lymphoblastic Leukemia.
NCT01813734	PHASE2	COMPLETED	Ponatinib in Advanced NSCLC w/ RET Translocations
NCT01838642	PHASE2	TERMINATED	Ponatinib for Advanced Medullary Thyroid Cancer
NCT01874665	PHASE2	COMPLETED	A Phase 2 Trial of Ponatinib in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor
NCT01935336	PHASE2	COMPLETED	Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers
NCT02398825	PHASE2	TERMINATED	Activity and Risk Profile of Ponatinib in Chronic Phase Patients With Chronic Myeloid Leukemia Resistant to Imatinib
NCT02428543	PHASE1/PHASE2	UNKNOWN	Ponatinib for FLT3-ITD Acute Myelogenous Leukemia
NCT02467270	PHASE2	COMPLETED	Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses
NCT02478164	PHASE2	COMPLETED	Trial of Ponatinib in Patients With Bevacizumab-Refractory Glioblastoma
NCT02776605	PHASE2	UNKNOWN	Ponatinib With Chemotherapy for Young Adults Ph Positive Acute Lymphoblastic Leukemia
NCT02829840	PHASE1/PHASE2	WITHDRAWN	Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML)
NCT03171389	PHASE2	UNKNOWN	POETIG Trial - POnatinib After rEsisTance to Imatinib in GIST
NCT03690115	PHASE2	COMPLETED	Study of Ponatinib (Iclusig) for Prevention of Relapse After Allogeneic Stem Cell Transplantation (allo-SCT) in FLT3-ITD AML Patients
NCT03704688	PHASE1/PHASE2	COMPLETED	Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer
NCT03807479	PHASE2	TERMINATED	Study in Patients With Chronic Leukemia
NCT03838692	PHASE2	WITHDRAWN	Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer
NCT03895671	PHASE2	UNKNOWN	PONAZA : A COMBINATION OF PONATINIB AND 5-AZACITIDINE IN CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE OR IN MYELOID BLAST CRISIS
NCT04043676	PHASE2	UNKNOWN	Consolidation Treatment With Ponatinib 15 mg on Treatment Free-Remission Rate in Patients With Chronic Myeloid Leukemia

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

182 molecules share ≥1 primary target. Top 60 by shared-target count:

Molecule	Source	Status	Shared targets
AFATINIB	ChEMBL + PubChem	Phase 4 (approved)	ABL1, CDK19, CDK8, RET, RIPK1, RIPK2, RIPK3
CRIZOTINIB	ChEMBL + PubChem	Phase 4 (approved)	ABL1, CDK19, CDK8, RET, RIPK1, RIPK2, RIPK3
GEFITINIB	ChEMBL + PubChem	Phase 4 (approved)	ABL1, CDK19, CDK8, RET, RIPK1, RIPK2, RIPK3
PAZOPANIB	ChEMBL + PubChem	Phase 4 (approved)	ABL1, CDK19, CDK8, RET, RIPK1, RIPK2, RIPK3
QUIZARTINIB	ChEMBL + PubChem	Phase 4 (approved)	ABL1, CDK19, CDK8, RET, RIPK1, RIPK2, RIPK3
SORAFENIB	ChEMBL + PubChem	Phase 4 (approved)	ABL1, CDK19, CDK8, RET, RIPK1, RIPK2, RIPK3
FORETINIB	ChEMBL	Phase 2	ABL1, CDK19, CDK8, RET, RIPK1, RIPK2, RIPK3
Selumetinib	PubChem	Approved	ABL1, CDK19, CDK8, RET, RIPK1, RIPK2, RIPK3
AXITINIB	ChEMBL + PubChem	Phase 4 (approved)	ABL1, CDK19, RET, RIPK1, RIPK2, RIPK3
FEDRATINIB	ChEMBL + PubChem	Phase 4 (approved)	ABL1, CDK19, RET, RIPK1, RIPK2, RIPK3
BOSUTINIB	ChEMBL + PubChem	Phase 4 (approved)	ABL1, CDK19, RET, RIPK2, RIPK3
ERLOTINIB	ChEMBL + PubChem	Phase 4 (approved)	ABL1, CDK19, RET, RIPK2, RIPK3
LAPATINIB	ChEMBL + PubChem	Phase 4 (approved)	ABL1, CDK19, RET, RIPK2, RIPK3
SUNITINIB	ChEMBL + PubChem	Phase 4 (approved)	ABL1, CDK19, RET, RIPK1, RIPK3
VANDETANIB	ChEMBL + PubChem	Phase 4 (approved)	ABL1, CDK19, RET, RIPK2, RIPK3
LINIFANIB	ChEMBL	Phase 3	ABL1, CDK19, CDK8, RET, RIPK1
DORAMAPIMOD	ChEMBL	Phase 2	ABL1, CDK19, CDK8, RET, RIPK2
RAF-265	ChEMBL	Phase 2	ABL1, CDK19, RET, RIPK1, RIPK2
CABOZANTINIB	ChEMBL + PubChem	Phase 4 (approved)	ABL1, RET, RIPK2, RIPK3
DABRAFENIB	ChEMBL + PubChem	Phase 4 (approved)	ABL1, RIPK1, RIPK2, RIPK3
dacomitinib	ChEMBL + PubChem	Phase 4 (approved)	ABL1, RET, RIPK2, RIPK3
Fostamatinib	ChEMBL + PubChem	Phase 4 (approved)	ABL1, RET, RIPK2, RIPK3
IBRUTINIB	ChEMBL + PubChem	Phase 4 (approved)	ABL1, RET, RIPK2, RIPK3
LENVATINIB	ChEMBL + PubChem	Phase 4 (approved)	ABL1, RET, RIPK2, RIPK3
MIDOSTAURIN	ChEMBL + PubChem	Phase 4 (approved)	ABL1, CDK19, RET, RIPK3
NILOTINIB	ChEMBL + PubChem	Phase 4 (approved)	ABL1, CDK19, RET, RIPK3
REGORAFENIB	ChEMBL + PubChem	Phase 4 (approved)	ABL1, RET, RIPK2, RIPK3
RUXOLITINIB	ChEMBL + PubChem	Phase 4 (approved)	ABL1, CDK19, RET, RIPK3
TIVOZANIB	ChEMBL + PubChem	Phase 4 (approved)	ABL1, RET, RIPK2, RIPK3
TOFACITINIB	ChEMBL + PubChem	Phase 4 (approved)	ABL1, CDK19, RET, RIPK3
CANERTINIB	ChEMBL	Phase 3	ABL1, RET, RIPK2, RIPK3
LESTAURTINIB	ChEMBL	Phase 3	ABL1, CDK8, RET, RIPK2
MOTESANIB	ChEMBL	Phase 3	ABL1, RET, RIPK2, RIPK3
SARACATINIB	ChEMBL	Phase 3	ABL1, RET, RIPK2, RIPK3
TESEVATINIB	ChEMBL	Phase 3	ABL1, RET, RIPK2, RIPK3
BAFETINIB	ChEMBL	Phase 2	ABL1, RET, RIPK2, RIPK3
CEP-32496	ChEMBL	Phase 2	ABL1, RET, RIPK2, RIPK3
GOLVATINIB	ChEMBL	Phase 2	ABL1, RET, RIPK2, RIPK3
REBASTINIB	ChEMBL	Phase 2	ABL1, RET, RIPK1, RIPK3
TOZASERTIB	ChEMBL	Phase 2	ABL1, CDK19, RET, RIPK1
Binimetinib	PubChem	Approved	ABL1, RET, RIPK2, RIPK3
Idelalisib	PubChem	Approved	ABL1, RET, RIPK2, RIPK3
Trametinib	PubChem	Approved	ABL1, RET, RIPK2, RIPK3
CERITINIB	ChEMBL + PubChem	Phase 4 (approved)	ABL1, RET, RIPK3
ENTRECTINIB	ChEMBL + PubChem	Phase 4 (approved)	ABL1, RET, RIPK3
GILTERITINIB	ChEMBL + PubChem	Phase 4 (approved)	RET, RIPK2, RIPK3
IMATINIB	ChEMBL + PubChem	Phase 4 (approved)	ABL1, CDK19, RIPK3
NERATINIB	ChEMBL + PubChem	Phase 4 (approved)	ABL1, CDK19, RIPK3
VEMURAFENIB	ChEMBL + PubChem	Phase 4 (approved)	RET, RIPK2, RIPK3
DASATINIB	ChEMBL	Phase 4 (approved)	ABL1, RET, RIPK2
NINTEDANIB	ChEMBL	Phase 4 (approved)	ABL1, RET, RIPK1
ALISERTIB	ChEMBL	Phase 3	ABL1, CDK8, RET
ALVOCIDIB	ChEMBL	Phase 3	ABL1, CDK19, CDK8
BRIVANIB	ChEMBL	Phase 3	ABL1, RET, RIPK2
CEDIRANIB	ChEMBL	Phase 3	ABL1, RET, RIPK2
DOVITINIB	ChEMBL	Phase 3	ABL1, RET, RIPK1
POZIOTINIB	ChEMBL	Phase 3	RET, RIPK2, RIPK3
VATALANIB	ChEMBL	Phase 3	CDK19, CDK8, RET
DEFOSBARASERTIB	ChEMBL	Phase 2	ABL1, RET, RIPK2
FEXAGRATINIB	ChEMBL	Phase 2	RIPK1, RIPK2, RIPK3